应用CRISPR-Cas9编辑的T细胞靶向细胞内免疫检查点CISH治疗转移性结直肠癌患者:一项首次人体、单中心、1期试验
这项首次人体单中心1期试验在转移性胃肠道上皮癌患者中评估了CRISPR-Cas9敲除CISH的新生抗原反应性肿瘤浸润淋巴细胞(TIL)的安全性和抗肿瘤活性。12例患者接受输注,所有患者均发生治疗相关严重不良事件,最常见为血液学事件;6例(50%)在第28天疾病稳定,1例微卫星高度不稳定结直肠癌患者获得持续完全缓解(>21个月)。
要点
- 12例转移性胃肠道上皮癌患者接受CISH敲除TIL输注,全部发生治疗相关严重不良事件。
- 6例(50%)在第28天疾病稳定,4例(33%)在第56天疾病稳定持续。
- 1例微卫星高度不稳定结直肠癌患者获得持续完全缓解(>21个月)。
核心结论
- 结果表明,通过输注新生抗原反应性CISH敲除TIL抑制免疫检查点CISH具有安全性和潜在抗肿瘤活性,对检查点抑制剂免疫治疗难治的晚期转移性癌症患者具有意义,并首次提供了一种新型细胞内检查点可被靶向并产生治疗效应的证据。
研究设计与样本
- 首次人体、单中心、1期试验,纳入18-70岁转移性胃肠道上皮癌患者,至少一线标准治疗进展,有可测量病灶且至少一个病灶可切除用于TIL制备,ECOG体能状态0或1。
- 从肿瘤活检获取TIL,基于新生抗原反应性扩增,经CRISPR-Cas9介导CISH敲除,在非清髓性淋巴细胞清除化疗后静脉输注,随后给予高剂量IL-2。
- 主要终点为新生抗原反应性CISH敲除TIL给药的安全性,关键次要终点为客观影像学缓解、无进展生存和总生存。
- 2020年5月12日至2022年9月16日共入组22例参与者(1例因首次尝试TIL未扩增而两次入组),其中10例女性、11例男性(自我定义),1例亚洲人、其余为白人(自我定义)。
- 成功为19例(86%)患者制备CISH敲除TIL产品,其中12例(63%)接受自体CISH敲除TIL输注。
主要发现
- 研究中位随访时间为129天(IQR 15-283)。
- 全部12例(100%)患者发生治疗相关严重不良事件,最常见的3-4级不良事件包括血液学事件(12例[100%],归因于预备性淋巴细胞清除化疗方案或IL-2的预期效应)、疲乏(4例[33%])和厌食(3例[25%])。
- 研究期间患者任何原因死亡归因于所研究的基礎疾病(转移性胃肠道癌)及相关并发症(10例)或感染(1例5级败血症)。
- 未发生严重(≥3级)细胞因子释放或神经毒性事件。
- 12例患者中6例(50%)在第28天疾病稳定,4例(33%)在第56天疾病稳定持续;1例对anti-PD1/CTLA-4治疗难治的微卫星高度不稳定结直肠癌年轻成人患者获得持续完全缓解(>21个月)。
关键数值与推荐
- 淋巴细胞清除化疗:环磷酰胺60 mg/kg每剂,于研究第-6天和第-5天给药;氟达拉滨25 mg/m2每剂,于第-7天至第-3天给药。
- 随后给予高剂量IL-2(阿地白介素)720 000 IU/kg每剂。
- 主要终点为新生抗原反应性CISH敲除TIL给药的安全性;关键次要终点为客观影像学缓解、无进展生存和总生存。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the past decade, immunotherapeutic strategies-mainly targeting the PD-1-PD-L1 immune checkpoint axis-have altered cancer treatment for many solid tumours, but few patients with gastrointestinal forms of cancer have benefited to date. There remains an urgent need to extend immunotherapy efficacy to more patients while addressing resistance to current immune checkpoint inhibitors. The aim of this study was to determine the safety and anti-tumour activity of knockout of CISH, which encodes cytokine-inducible SH2-containing protein, a novel intracellular immune checkpoint target and a founding member of the SOCS family of E3-ligases, using tumour infiltrating lymphocyte (TILs) genetically edited with CRISPR-Cas9 in patients with metastatic gastrointestinal epithelial cancers. METHODS: For this first-in-human, single-centre, phase 1 trial, patients aged 18-70 years with a diagnosis of metastatic gastrointestinal epithelial cancer with progressive disease following at least one first line standard therapy, measurable disease with at least one lesion identified as resectable for TIL generation and at least one other lesion meeting RECIST criteria as measurable to serve as an indicator of disease response, and an ECOG performance status of 0 or 1 were screened and enrolled if meeting these and all other eligibility criteria. TILs procured from tumour biopsies were expanded on the basis of neoantigen reactivity, subjected to CRISPR-Cas9-mediated CISH knockout, and infused intravenously into 12 patients after non-myeloablative lymphocyte depleting chemotherapy (cyclophosphamide 60 mg/kg per dose on study days -6 and -5, and fludarabine 25 mg/m2 per dose on days -7 to -3) followed by high-dose IL-2 (aldesleukin; 720 000 IU/kg per dose). The primary endpoint was safety of administration of neoantigen-reactive TILs with knockout of the CISH gene, and a key secondary endpoint was anti-tumour activity measured as objective radiographic response and progression-free and overall survival. This study is registered with ClinicalTrials.gov, NCT04426669, and is complete. FINDINGS: Between May 12, 2020, and Sept 16, 2022, 22 participants were enrolled in the trial (one patient was enrolled twice owing to lack of TIL outgrowth on the first attempt); ten patients were female, and 11 were male (self-defined). One patient was Asian, the remainder were White (self-defined). We successfully manufactured CISH knockout TIL products for 19 (86%) of the patients, of whom 12 (63%) received autologous CISH knockout TIL infusion. The median follow-up time for the study was 129 days (IQR 15-283). All 12 (100%) patients had treatment-related severe adverse events. The most common grade 3-4 adverse events included haematological events (12 patients [100%]) attributable to the preparative lymphodepleting chemotherapy regimen or expected effects of IL-2, fatigue (four patients [33%]), and anorexia (three patients [25%]). Deaths of any cause for patients on study were attributed to the underlying disease under study (metastatic gastrointestinal cancer) and related complications (10 patients) or infection (grade 5 septicaemia in one patient). There were no severe (≥grade 3) cytokine release or neurotoxicity events. Six (50%) of 12 patients had stable disease by day 28, and four (33%) had stable disease ongoing at 56 days. One young adult patient with microsatellite-instability-high colorectal cancer refractory to anti-PD1/CTLA-4 therapies had a complete and ongoing response (>21 months). INTERPRETATION: These results support the safety and potential antitumour activity of inhibiting the immune checkpoint CISH through the administration of neoantigen-reactive CISH-knockout TILs, with implications for patients with advanced metastatic cancers refractory to checkpoint inhibitor immunotherapies, and provide the first evidence that a novel intracellular checkpoint can be targeted with therapeutic effect. FUNDING: Intima Bioscience.
引用
- Lou E, Choudhry MS, Starr TK, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025. PMID: 40315882. doi:10.1016/S1470-2045(25)00083-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。